<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621413</url>
  </required_header>
  <id_info>
    <org_study_id>isoray_cs131_pc01</org_study_id>
    <nct_id>NCT00621413</nct_id>
  </id_info>
  <brief_title>Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer</brief_title>
  <official_title>Dosimetric and Morbidity Outcomes of Cs-131 Brachytherapy in Combination With External Beam Radiation Therapy in Subjects With Intermediate to High Risk Adenocarcinoma of the Prostate: An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IsoRay Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IsoRay Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe PSA response and incidence of side effects in&#xD;
      patients diagnosed with intermediate to high risk prostate cancer and treated with Cesium-131&#xD;
      in combination of external beam therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never moved forward due to no accrual&#xD;
  </why_stopped>
  <start_date type="Anticipated">February 2007</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The analysis of dosimetric data resultant from Cs-131 permanent prostate brachytherapy in combination with external beam radiation therapy in the setting of intermediate to high risk cancer of the prostate.</measure>
    <time_frame>5 years</time_frame>
    <description>Data collected for analysis will be total therapeutic dose delivered to the prostate by the Cs-131 brachytherapy implant treatment in units of Gy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The analysis of treatment related morbidities following Cs-131 prostate brachytherapy in combination with external beam therapy for intermediate to high risk cancer of the prostate.</measure>
    <time_frame>5 years</time_frame>
    <description>Data collected for analysis will be the EPIC prostate cancer quality of life questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The analysis of PSA control rates following Cs-131 prostate brachytherapy in combination with external beam therapy for intermediate to high risk cancer of the prostate.</measure>
    <time_frame>5 years</time_frame>
    <description>Data collected for analysis will be PSA measurements.</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        diagnosed patients with intermediate to high risk cancer of the prostate. Patient will be&#xD;
        in a Radiation Oncology setting.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Clinical stage T1c - T2c (AJCC 6th Edition), NX/N0, M0&#xD;
&#xD;
          -  Karnofsky Performance Score of 90 to 100&#xD;
&#xD;
          -  Greater than or equal to 18 years of age&#xD;
&#xD;
          -  Prostate volumes by TRUS ≤ 60 cc&#xD;
&#xD;
          -  I-PSS score &lt; 15 (alpha blockers allowed)&#xD;
&#xD;
          -  Signed study-specific informed consent form prior to study entry&#xD;
&#xD;
        Intermediate Risk prostate cancer as determined by the following:&#xD;
&#xD;
          -  Gleason sum of 7; PSA less than 10.1 ng/ml; Stage T2a or less&#xD;
&#xD;
          -  Gleason sum 6 or less; PSA &gt;10.0 and &lt; 20.1ng/ml; Stage T2a or less&#xD;
&#xD;
          -  Gleason sum 6 or less; PSA &lt; 10.1; Stage T2b&#xD;
&#xD;
        High risk prostate cancer as determined by the following:&#xD;
&#xD;
          -  Any Gleason Sum; PSA greater than 20 ng/ml; Stage T2c or less&#xD;
&#xD;
          -  Gleason Sum &gt; 7; Any PSA; Stage T2c or less&#xD;
&#xD;
          -  Any Gleason Sum; Any PSA; Stage T2c&#xD;
&#xD;
          -  Any two or three intermediate risk factor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lymph node involvement (N1)&#xD;
&#xD;
          -  Evidence of distant metastases (M1)&#xD;
&#xD;
          -  Any hormonal blockade or therapy that:&#xD;
&#xD;
               -  Has persisted for more than 6 months by time of protocol screening; OR&#xD;
&#xD;
               -  Is ongoing within 3 months of study enrollment&#xD;
&#xD;
          -  Radical surgery for carcinoma of the prostate&#xD;
&#xD;
          -  Prior pelvic radiation&#xD;
&#xD;
          -  Previous or concurrent cancers other than basal, in situ, or squamous cell skin&#xD;
             cancers unless disease-free for ≥ 5 years&#xD;
&#xD;
          -  Major medical or psychiatric illness, which in the investigator's opinion, would&#xD;
             prevent completion of treatment and would interfere with follow-up&#xD;
&#xD;
          -  Hip prosthesis&#xD;
&#xD;
          -  Inability or refusal to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Sylvester, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Prostate Institute / Swedish Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Kurtzman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mills Peninsula Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology Services Foundation</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisenhower Medical Center</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorthory Schneider Cancer Center</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore Medical Accelerator</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Cancer Institute</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Prostate Institute / Swedish Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 12, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>intermediate risk</keyword>
  <keyword>high risk</keyword>
  <keyword>brachytherapy</keyword>
  <keyword>Cesium-131</keyword>
  <keyword>seed brachytherapy</keyword>
  <keyword>intermediate and high risk cancer of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

